ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients

Phase 29MW1911Neutral

AI Analysis

Summary

Mabwell announced Phase Ib/IIa clinical results for anti-ST2 monoclonal antibody 9MW1911 in COPD patients at ERS 2026. The article provides minimal outcome details beyond the announcement of results presentation.

Clinical Trial Data

Phase

Ib/IIa

Importance:6/10

Sentiment:

0.00

Phase_2_DataMonoclonal_AntibodyCOPDST2_Target

Related Companies

$INBP

Read the original article

Published by PR Newswire Biotech on September 4, 2026 1:00 PM

Read Original